Cytotoxic T cell immunity to human cytomegalovirus glycoprotein B

Journal of Medical Virology

Volumn 49, Issue 2, 1996, Pages 124-131

  Hopkins, J I ^a   Fiander, A N ^a   Evans, A S ^a   Delchambre, M ^b   Gheysen, D ^b   Borysiewicz, L K ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Smith Kline Beecham ^*  (Belgium)

Author keywords

Cytotoxic; Glycoprotein B; Human cytomegalovirus; T cell

Indexed keywords

GLYCOPROTEIN B; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; PREGNANCY;

ADULT; BASE SEQUENCE; CELLS, CULTURED; CYTOMEGALOVIRUS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, CELLULAR; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC; VIRAL ENVELOPE PROTEINS;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 0029885391     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199606)49:2<124::AID-JMV9>3.0.CO;2-7     Document Type: Article

References (28)

1. Alp NJ, Allport TD, Van Zanten, Rodgers B, Sissons JGP, Borysiewicz LK (1991): Fine specificity of cellular immune responses in humans to human cytomegalovirus immediate-early 1 protein. Journal of Virology 65:4812-4820.
2. Boppana SB, Pass RF, Britt WJ (1993): Virus specific anibody responses in mothers and their newborn infants with asymptomatic congenital cytomegalovirus infections. Journal of Infectious Diseases 167:72-77.
3. Borysiewicz LK, Morris SM, Page J, Sissons JGP (1983): Human cytomegalovirus specific cytotoxic T lymphocytes - requirements for in vitro generation and specificity. European Journal of Immunology 13:814-809.
4. Borysiewicz LK, Graham S, Hickling JK, Mason PD, Sissons JGP (1988a): Human cytomegalovirus-specific cytotoxic T cells: Their precursor frequency and stage specificity. European Journal of Immunology 18:269-275.
5. Borysiewicz LK, Hickling JK, Graham S, Sinclair J, Cranage MP, Smith GL, Sissons JGP (1988b): Human eytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognising the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. Journal of Experimental Medicine 168:919-931.
6. Britt WJ (1984) Neutralizing antibodies detect a disulphide-linked glycoprotein complex within the envelope of human cytomegalovirus. Virology 135:369-378.
7. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB (1990): Cell surface expression of human cytomegalovirus (HCMV) gp-116(gB): Use of HCMV recombinant vaccinia virus-infected cells in analysis of the human nuetralizing antibody response. Journal of Virology 64:1079-1085.
8. Cranage MP, Kouzarides T, Bankier AT et al (1986): Identification of the human cytomegalovirus glycoprotein B gene and induction of nuetralizing antibodies via its expression in recombinant vaccinia virus. The EMBO Journal 5:3057-3063.
9. Curtsinger JM, Liu YC, Redeke R, Bryon MK, Fuad S, Bach FH, Gehrz RC (1993): Molecular analysis of the immune response to human cytomegalovirus glycoprotein B (gB). II: Low gB-specific T and B cell responses are associated with expression of certain HLA-DR alleles. Journal of General Virology. 75:301-307.
10. Elek SD, Stern H (1974): Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1-4.
11. Farrar GH, Bull JR, Greenaway PJ (1986): Prospects for the clinical management of human cytomegalovirus infections. Vaccine 4:217-224.
12. Gilbert MJ, Riddell SR, Li CR, Greenberg PD (1993): Selective interference with class I major histocompatibility complex presentation of the major immediate early protein following infection with human cytomegalovirus. Journal of Virology 67:3461-3469.
13. Gretch DR, Kari B, Rasmussen L et al (1988a): Identification and characterisation of three distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus. Journal of Virology 62:875-881.
14. Gretch DR, Gehrz RC, Stinski MF (1988b): Characterisation of a human cytomegalovirus glycoprotein complex (gel). Journal of General Virology 69:1205-1215.
15. Krech U (1973): Complement-fixing antibodies against cytomegalovirus in different parts of the world. Bull. WHO 49:103-106.
16. Liu YN, Klaus A, Kari B, Stinski MF, Eckhardt J, Gehrz RC (1991): The N-terminal amino acids of the envelope glycoproteins of human cytomegalovirus stimulates both B- and T- cell immune responses in humans. Journal of Virology 65:1644-1648.
17. Montgomery R, Youngblood L, Medeans (1972): Recovery of cytomegalovirus from the cervix in pregnancy. Pediatrics 49:524.
18. Plotkin SA, Starr SE, Friedman HM, Gonzol E, Brayman K (1990): Vaccines for the prevention of human cytomegalovirus infection. Review of Infectious Diseases. 12:S827-S838.
19. Rapp M, Messerle M, Lucin P and Koszinowski UH (1993): In vivo protection studies with HCMV glycoproteins gB and gH expressed by vaccinia virus. In Michelson, Plotkin (eds): "Multidisciplinary Appraoch to Understanding of Ctymegalovirus Disease." Excerpta Medica, pp 327-333.
20. Reddehase MJ, Mutter U, Munch K, Buhring KH, Koszinowski UH (1987): CD8+ T lymphocytes specific for muring cytomegalovirus immediate early antigens mediate protective immunity. Journal of Virology 61:3102.
21. Riddell SR, Reusser P, Greenberg (1991): Cytotoxic T cells specific for cytomegalovirus: A potential therapy for immunocompromised patients. Review of Infectious Diseases 13(suppl 11):S966-973.
22. Roizman B (1982): The Family Herpesviridae: general description, taxonomy and classification. In Roizman B (ed): "The Herpesviruses 1." New York: Plenum Press, pp 1-23.
23. Stagno S, Reynolds DW, Huang ES, Thames SD, Smith RJ, Alford CA (1977): Congenital cytomegalovirus infection. New England Journal of Medicine 296:1254-1258.
24. Stern H, Hannington, Booth J, Moncrieff D (1986): An early marker of feotal infection after primary cytomegalovirus infection in pregnancy. British Medical Journal 292:718-720.
25. Terasaki, Bernoco D, Park MS,Ozturk G, Iwaki Y (1978): Microdroplets testing for HLAA, B, C and D antigens. American Journal of Clinical Pathology 69:103-120.
26. Utz U, Koenig S, Coligan JE, Biddison WE (1992): Presentation of three different viral peptides, HTLV-1 TAX, HCMVgB and influenza virus M1 is determined by common structural features of the HLA-A2 ·1 molecule. The Journal of Immunology 149(1):214-221.
27. Walls EV, Crawford DH (1987): Generation of human B lymphoblastoid cell lines using Epstein-Barr virus. In Klaus GGB (ed): "Lymphocytes, a Practical Approach." Oxford: IRL Press Limited., pp 149-162.
28. Yeager AS, Grumet FC, Hafleigh EB, AM Arnn, Bradley JE, Prober CG (1981): Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. Journal of Pediatrics 98:281-287.